Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
ALT Stock Chart & Stats
$5.10
$0.16(2.19%)
At close: 4:00 PM EST
$5.10
$0.16(2.19%)
Day’s Range― - ―
52-Week Range$2.90 - $10.88
Previous CloseN/A
Volume1.55M
Average Volume (3M)2.93M
Market Cap
$532.15M
Enterprise Value$142.19M
Total Cash (Recent Filing)$210.78M
Total Debt (Recent Filing)$15.90M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Mar 26, 2026EPS Estimate
-0.26Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding104,342,384
10 Day Avg. Volume3,360,683
30 Day Avg. Volume2,925,139
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)4.14
Price to Sales (P/S)25596.73
P/FCF Ratio-6.41
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue7.11K
Enterprise Value/Gross Profit-9.52
Enterprise Value/Ebitda-1.70
Forecast
1Y Price Target
$13.00Price Target Upside154.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.01
Revenue Forecast (FY)$8.13K
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressAltimmune is positioned for a key inflection point with the highly-anticipated 48-week readout from pemvidutide’s Phase 2b trial in metabolic dysfunction-associated steatohepatitis and an in-person end-of-phase 2 meeting with the FDA.
Leadership And StrategyAltimmune’s update reinforced continued clinical, regulatory, and commercial momentum, highlighting rapid execution across programs, growing confidence in the durability of non-invasive test effects, and an expanding leadership team positioned for Phase 3 and launch readiness.
Market Position And MechanismManagement reiterated that pemvidutide’s dual GLP-1/glucagon mechanism offers a differentiated path in an increasingly consolidated MASH landscape, combining potent weight loss and direct hepatic benefit with a best-in-class tolerability profile.
Bears Say
Long-term Efficacy ConcernsInvestors will likely have to wait for years before lingering questions about the treatment's efficacy are resolved.
Market CompetitionPemvidutide lacks clear differentiation in the increasingly competitive MASH market.
Regulatory ChallengesNon-invasive tests cannot form the basis of regulatory approval at this time.
Altimmune News
ALT FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was $2.90 and its highest was $10.88 in the past 12 months.
What is Altimmune Inc’s market cap?
Altimmune Inc’s market cap is $532.15M.
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Mar 26, 2026 which is in 120 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Nov 06, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.272 by $0.062.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -0.26.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 104,342,384 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.272. Following the earnings report the stock price went up 5.067%.
Which hedge fund is a major shareholder of Altimmune Inc?
Currently, no hedge funds are holding shares in ALT
Altimmune Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (154.90% Upside)
$13.00 (154.90% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 142.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.24%
12-Months-Change
Fundamentals
Return on Equity
-52.61%
Trailing 12-Months
Asset Growth
47.73%
Trailing 12-Months
Company Description
Altimmune Inc
Altimmune, Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of infectious diseases, liver diseases, and immune-related conditions. The company specializes in the development of immunotherapy products and is known for its innovative approach to vaccine development using its proprietary technologies. Altimmune's core product pipeline includes candidates for respiratory and liver diseases, aiming to address significant unmet medical needs.
ALT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant financial growth, clinical progress in key trials, and strategic leadership enhancements. However, there are challenges related to the timing of clinical operations and dependency on regulatory changes, which could impact future trial designs and approvals.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$13.00
▲(154.90% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.62% Insiders
9.23% Mutual Funds
1.31% Other Institutional Investors
78.19% Public Companies and Individual Investors